Publication

Phase 3 randomized EORTC 1325-MG/KEYNOTE-054 study results: pembrolizumab versus placebo after complete resection in patients with high-risk stage III melanoma.

Khattak, A
; 
Robert, C
; 
Blank, C
; 
Mandala, M
; 
Long, G
; 
Atkinson, V
; 
Dalle, S
; 
Haydon, A
; 
Lichinitser, M
; 
Carlino, M
... show 10 more
Citations
Altmetric:
Abstract
Authors
Khattak, A
Robert, C
Blank, C
Mandala, M
Long, G
Atkinson, V
Dalle, S
Haydon, A
Lichinitser, M
Carlino, M
Sandhu, S
Larkin, J
Puig, S
Ascierto, P
Rutkowski, P
Schadendorf, D
Lorigan, Paul C
Ibrahim, N
Suciu, S
Eggermont, A
Affiliation
Fiona Stanley Hospital/University of Western Australia, Perth, Australia
Description
Date
2018
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Phase 3 randomized EORTC 1325-MG/KEYNOTE-054 study results: pembrolizumab versus placebo after complete resection in patients with high-risk stage III melanoma. 2018, 14: 48-48 Asia Pac J Clin Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/621219
Embedded videos